As cell therapy development advances toward broader patient access, manufacturing strategy increasingly determines scalability, cost, and commercial feasibility. Autologous models remain constrained by patient-specific production, complex logistics, capacity limits, and attrition during manufacturing and QC. Traditional allogeneic approaches improve scale but face donor variability and finite expansion. This article examines how iPSC-based platforms, supported by a renewable master cell bank, can enable standardized, off-the-shelf manufacturing. Using Cellistic’s Echo™-NK GMP platform for iPSC-derived NK cells as a case study, the analysis models potential COGS reductions of up to 95%, with unit economics driven primarily by batch yield and facility utilization.